* FDA approves NerPharMa to manufacture drug pixantrone
* FDA's final decision on drug expected by April 23
March 8 Cell Therapeutics Inc (CTIC.O) said
U.S. health regulators approved the facility to manufacture its
experimental cancer drug currently under review, sending its
shares up 14 percent before the bell.
The company said the U.S. Food and Drug Administration
completed its inspection of the facility at NerPharMa, which
belongs to Italy-based Nerviano Medical Sciences, and has found
the site in compliance and acceptable for continued
manufacturing of the drug pixantrone.
The drug is under review as a treatment for
relapsed/refractory aggressive non-Hodgkin's lymphoma and the
FDA is expected to make a final decision on approval by April
Shares of Cell Therapeutics closed at 90 cents Friday on
Nasdaq. They were at $1.02 Monday before the bell.
(Reporting by Jennifer Robin Raj in Bangalore; Editing by
Ratul Ray Chaudhuri)